Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer - Takeaways - MDSpire

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer

  • By

  • Yulu Wang

  • Chengyang Luo

  • Yueze Li

  • Jiayu Pei

  • Dian Wang

  • Pei Wang

  • Jing Li

  • June 12, 2026

  • 0 min

Share

  • 1

    The study developed a prognostic model using inflammatory biomarkers to predict immunotherapy response in patients with recurrent or metastatic cervical cancer.

  • 2

    A total of 263 patients were analyzed, with 185 in the training cohort and 78 in the validation cohort for model development.

  • 3

    Optimal cutoff values for inflammatory markers were established, including neutrophil-to-lymphocyte ratio and systemic immune-inflammation index.

  • 4

    The LASSO-Cox model demonstrated strong predictive performance for overall survival and progression-free survival in both training and validation sets.

  • 5

    A nomogram was created, indicating poorer survival outcomes for high-risk patients based on the inflammatory biomarker-based prognostic model.

Original Source(s)

Inflammatory biomarker-based prognostic model for immunotherapy outcomes in patients with recurrent or metastatic cervical cancer

  • by Yulu Wang, Chengyang Luo, Yueze Li, Jiayu Pei, Dian Wang, Pei Wang, Jing Li

  • June 12, 2026

Related Content

L-arginine metabolism in breast cancer: mechanisms and therapeutic targets

Diagnostic performance of 18F-FDG PET-CT and SPECT for bone metastases from colorectal cancer: a retrospective study

Roving Reporter Asks: What Emerging Approaches Could Define the Next Wave of Advanced Therapies?

IBTV speaks with industry leaders at Advanced Therapies London 2026 to explore the emerging modalities and technologies that could shape the next era of cell and gene therapy

  • June 11, 2026

  • 1 min